Drug intelligence / Profile preview

Pistacal-D3

Development stage: Unknown
Lead developer: Pistacia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Pistacal-D3 is an approved, marketed oral nutraceutical combination of coral calcium and vitamin D3 (cholecalciferol) developed by Pistacia Pharmaceuticals. It is formulated to provide natural ionized calcium with high bioavailability and absorption compared to elemental calcium, while minimizing common gastrointestinal side effects such as flatulence, belching, and constipation. Pistacal-D3 is indicated for calcium and vitamin D supplementation to support bone health and is used in conditions such as osteoporosis, osteomalacia, bone loss, and fractures, as well as during pregnancy, lactation, puberty, and post-menopause.

Brand names: Pistacal-D3Pistacal-D-3Pistacal-D 3
Other names: coral calcium + cholecalciferolcoral calcium + vitamin D3

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Pistacal-D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pistacal-D3.